Ocular surface disease (OSD) is a term that encompasses a range of eye conditions, including dry eye syndrome (DES), conjunctivitis, and keratitis. It is estimated that nearly 40% of patients seen by eye care professionals are affected by OSD, posing a daily challenge for accurate diagnosis and treatment. This complexity stems from the multiple factors involved in the diagnosis and treatment of OSD, particularly DES, and the continuous advancements in OSD diagnostics and therapeutics.
Table of Contents
Diagnostic Evaluations for OSD
Diagnostic evaluations for OSD typically include external and slit lamp examinations. There is a preference for utilizing neutral density filters and broad beam illumination, and the preferred diagnostic signs include lid margin evaluation, meibomian gland assessment, vital dye-assisted corneal staining, tear breakup time measurement, and tear meniscus size measurement. Biomarkers such as MMP-9, lactoferrin, and IgE are less commonly used.
Eye Care Professionals (ECPs) also utilize dry eye questionnaires for screening and monitoring symptom improvement, with DES being divided into evaporative, aqueous deficient, and combined mechanism categories.
Treatment Options
Treatment for level 1 DES includes artificial tears and lid hygiene. However, levels 2 to 4 may require additional therapies such as topical steroids, immunosuppressant eye drops, and office-based procedures. Surgical procedures, including intravitreal injections, are associated with DES and require preoperative diagnosis, intraoperative surface protection, and postoperative rehabilitation. Long-term care for surgical-associated DES is essential to managing the disease effectively.
Innovation in Dry Eye Treatment
In the last year, significant advancements in dry eye treatment have been noted. The approval of Xdemvy for the management of Demodex blepharitis, a common comorbidity seen in almost 70% of dry eye disease patients, stands out. This medication has demonstrated long-term efficacy, durability, and safety in improving the symptoms of Demodex blepharitis. In addition, Miebo, a prescription for the management of evaporative dry eye disease, has been shown to stabilize the tear film and improve meibum secretions, providing noticeable results within weeks of therapy.
Challenges in Diagnosis and Management
Despite these advancements, several challenges remain in the diagnosis and management of OSD, particularly in low and middle-income countries. Infectious eye diseases contribute significantly to global visual impairment and blindness. The need for separate prevalence studies for ocular infections is emphasized because they frequently affect younger people.
Understanding the geographic distribution and modes of transmission of infectious eye diseases, as well as the potential impacts of global warming, conflict, food poverty, urbanization, and environmental degradation on their prevalence, is crucial. The need for enhanced global reporting networks and artificial intelligence systems for disease surveillance and monitoring is also highlighted.
Looking Forward: Clinical Trials and Future Research
Further research is being conducted to develop more effective treatments for OSD. A recent Phase 3 trial of SYL10111_V (tivanisiran) sponsored by PharmaMar subsidiary Sylentis, aimed to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome. Although the trial did not meet its primary endpoint, it contributes valuable information to the ongoing effort to improve the management of OSD.
In conclusion, the diagnosis and treatment of OSD are dynamic and challenging fields. While there have been significant advancements, much work remains to be done. Continued research, innovation, and a commitment to long-term care and maintenance therapy are essential to improving outcomes for patients with OSD.
